These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382 [TBL] [Abstract][Full Text] [Related]
30. Clinical trials with Alice strain, live, attenuated, serum inhibitor-resistant intranasal influenza A vaccine. Spencer MJ; Cherry JD; Powell KR; Sumaya CV; Garakian AJ J Infect Dis; 1975 Oct; 132(4):415-20. PubMed ID: 1102614 [TBL] [Abstract][Full Text] [Related]
31. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Bizanov G; Janakova L; Knapstad SE; Karlstad T; Bakke H; Haugen IL; Haugan A; Samdal HH; Haneberg B Scand J Immunol; 2005 Jun; 61(6):503-10. PubMed ID: 15963044 [TBL] [Abstract][Full Text] [Related]
32. A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group. Potter CW; Jennings R; McLaren C; Edey D; Stuart-Harris CH; Brady M J Hyg (Lond); 1975 Dec; 75(3):353-62. PubMed ID: 1059705 [TBL] [Abstract][Full Text] [Related]
33. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Coulter A; Harris R; Davis R; Drane D; Cox J; Ryan D; Sutton P; Rockman S; Pearse M Vaccine; 2003 Feb; 21(9-10):946-9. PubMed ID: 12547607 [TBL] [Abstract][Full Text] [Related]
34. Secretory immune response after nasal vaccination with live attenuated influenza viruses. Crifö S; Vella S; Filiaci F; Resta S; Rocchi G Rhinology; 1980 Jun; 18(2):87-92. PubMed ID: 7403787 [TBL] [Abstract][Full Text] [Related]
35. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice. Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202 [TBL] [Abstract][Full Text] [Related]
36. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine. Saito S; Ainai A; Suzuki T; Harada N; Ami Y; Yuki Y; Takeyama H; Kiyono H; Tsukada H; Hasegawa H Vaccine; 2016 Feb; 34(9):1201-7. PubMed ID: 26802605 [TBL] [Abstract][Full Text] [Related]
37. Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine. Oh Y; Ohta K; Kuno-Sakai H; Kim R; Kimura M Vaccine; 1992; 10(8):506-11. PubMed ID: 1621413 [TBL] [Abstract][Full Text] [Related]
38. Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine. Ruben FL; Potter CW; Stuart-Harris CH Arch Virol; 1975; 47(2):157-66. PubMed ID: 1119940 [TBL] [Abstract][Full Text] [Related]
39. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Muhamed G; Greenbaum E; Zakay-Rones Z Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048 [TBL] [Abstract][Full Text] [Related]
40. Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines. Slepushkin AN; Schild GC; Beare AS; Chinn S; Tyrrell DA J Hyg (Lond); 1971 Dec; 69(4):571-8. PubMed ID: 5002644 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]